Andrea Leith

Andrea Leith

Auto-generated profile, based on publicly available information

Andrea Leith

Adelphi Real World, Bollington, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in BMC Urology
Verified
Journal Article
Open access
PDF file
ALAndrea Leith
Andrea Leith
ARAmanda Ribbands
Amanda Ribbands
JKJeri Kim
Jeri Kim
ECEmily Clayton
Emily Clayton
LGLiane Gillespie-Akar
Liane Gillespie-Akar
SGSameer R. Ghate
Sameer R. Ghate
Background: Until five years ago, the metastatic hormone-sensitive prostate cancer (mHSPC) treatment landscape was dominated by the use of androgen deprivation therapy (ADT) alone. However, novel hormonal agents (NHAs) and chemotherapy are now approved for male patients with mHSPC. This study aimed to understand the impact NHA approvals had on mHSPC real-world treatment patterns and to identify the key factors associated with NHA or chemotherapy (± ADT) usage vs ADT alone. Methods: Data were collected from the Adelphi Prostate Cancer Disease Specific Programme (DSP)™, a point-in-time survey of physicians and their consulting patients conducted in the United States (US), five European countries (France, Germany, Italy, Spain, and the United Kingdom), and Japan between January and August 2020. Data were analysed using descriptive statistics for individual countries, regions, and all countries combined. Pairwise analyses were used to further investigate differences between treatment groups at global level. Results: 336 physicians provided data on 1195 mHSPC patients. Globally, at data collection, the most common mHSPC regimen initiated first was ADT alone (47%), followed by NHAs (± ADT) (31%, of which 21% was abiraterone, 8% was enzalutamide, and 2% was apalutamide) and chemotherapy (± ADT) (19%). The highest rates of ADT alone usage were observed in Japan (78%) and Italy (66%), and the lowest in Spain (34%) and in the US (36%). Our results showed that clinical decision making was driven by patient fitness, compliance, tolerance of adverse events, and balance of impact on quality of life vs overall survival. Conclusions: This real-world survey offered early insights into the evolving mHSPC treatment paradigm. It showed that in 2020, ADT alone remained the most common initial mHSPC therapy, suggesting that physicians may prefer using treatments which they are familiar and have experience with, despite clinical trial evidence of improved survival with NHAs or chemotherapy (± ADT) vs ADT alone. Results also indicated that physicians prescribed specific mHSPC treatments primarily based on the following criteria: patient preference, disease burden/severity, and the performance status and comorbidities of the patient. To fully appreciate the rapidly changing mHSPC treatment landscape and monitor NHA uptake, additional real-world studies are required.

22 March 2022 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
ALAndrea Leith
Andrea Leith
JKJeri Kim
Jeri Kim
ARAmanda Ribbands
Amanda Ribbands
ECEmily Clayton
Emily Clayton
LYLingfeng Yang
Lingfeng Yang
SGSameer R. Ghate
Sameer R. Ghate
Introduction Prostate cancer (PC) is the second most common cancer, and the fifth most common cause of cancer-related mortality among male patients, worldwide. In Europe and Japan, the incidence of PC in men in 2020 exceeded that of lung cancer. Although national and regional clinical guidelines for the treatment of metastatic castration-resistant prostate cancer (mCRPC) are available in Europe and Japan, a literature review did not identify a published comparison of differing guidelines, but identified a lack of studies reporting treatment patterns of approved mCRPC treatments in Europe and Japan in normal clinical practice. The objective of this real-world study was to compare national treatment guidelines and real-world treatment for mCRPC in Europe and Japan. Methods Physician-reported demographics, clinical characteristics, and treatment data of patients with mCRPC were drawn from the Adelphi Prostate Cancer Disease Specific Programme™, conducted in five European countries and Japan (2020) and analysed descriptively. Results All current treatment guidelines recommended the use of novel hormonal agents (NHA—abiraterone/enzalutamide) and chemotherapy (mainly docetaxel), with some intercountry differences, with NHA rechallenge accepted in Germany, Italy and Japan, but not in France, Spain or the United Kingdom. Overall, 271 physicians provided data for 1753 patients. At 1st-line (1L), the most common treatment was NHAs followed by (→) chemotherapy, in all countries. Chemotherapy was the most common 2nd-line (2L) treatment, except in Japan, where 2L NHA use was preferred, and Spain, where both were used equally. NHA → chemotherapy and chemotherapy → NHA were the first and second usual 1L → 2L sequence in most countries, except for France, where the second most common sequence was NHA → NHA, and Japan, with androgen deprivation therapy alone → NHA. Conclusion Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.

19 January 2022 in Future Oncology
Verified
Journal Article
Open access
ALAndrea Leith
Andrea Leith
ARAmanda Ribbands
Amanda Ribbands
JKJeri Kim
Jeri Kim
MLMatthew Last
Matthew Last
SBSophie Barlow
Sophie Barlow
SGSameer R Ghate
Sameer R Ghate
Aim: To assess homologous recombination repair mutation (HRRm) testing patterns in metastatic castration-resistant prostate cancer. Methods: A point-in-time, international survey conducted January–... Lay abstract Metastatic castration-resistant prostate cancer (mCRPC) is cancer that has spread beyond the prostate gland and that no longer responds to hormone therapy. Genetic testing is now recom...

1 October 2022 in Future Oncology
Verified
Journal Article
Open access
ALAndrea Leith
Andrea Leith
UKUrpo Kiiskinen
Urpo Kiiskinen
AGAllicia C Girvan
Allicia C Girvan
MJMin-Hua Jen
Min-Hua Jen
KKKeerun Khela
Keerun Khela
JPJames Piercy
James Piercy
Aim: To investigate the association of discordance in patient- and physician-reported symptoms on health-related quality of life (HRQoL) in hepatocellular carcinoma (HCC). Patients & methods: Data ...

1 January 2025 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
ALAndrea Leith
Andrea Leith
LHLewis Harrison
Lewis Harrison
JFJoão Diogo da Rocha Fernandes
João Diogo da Rocha Fernandes
LHLise M. Hagelund
Lise M. Hagelund
CLChristopher Lübker
Christopher Lübker
SCSilvia Capucci
Silvia Capucci
Background: The prevalence and socioeconomic impact of obesity are increasing in the United Kingdom; however, the effects of body mass index (BMI) and comorbidities on health-related quality of life (HRQoL) and work productivity in people living with overweight or obesity (PLwO) have not been fully described. Objective: To assess self-reported HRQoL and work productivity in PLwO in the United Kingdom, grouped by BMI and presence of cardiovascular and/or metabolic (CVM) comorbidities. Methods: Data used were from the Adelphi Obesity Disease Specific Programme™, a real-world cross-sectional survey (October 2023–April 2024). Physicians reported demographic and clinical characteristics for PLwO on a weight management program who were ≥18 years old and had current or previous BMI ≥30 kg/m2, or ≥27 kg/m2 with ≥1 weight-related comorbidity. The same PLwO completed the 36-item Short-Form Health Survey version 2 (SF-36v2) and Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) questionnaire. Results: Physicians provided data for 904 PLwO, of whom 119 completed the survey questionnaires. Mean age for PLwO was 51.7 years, 54% were women, the majority were White (69%), and 70% had ≥1 CVM comorbidity. SF-36v2 physical functioning scores were lower with higher BMI (P < .05). Scores for physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, and the physical component summary were lower (P < .05) in PLwO with cardiovascular comorbidities than in those without. PLwO with metabolic comorbidities had lower scores than those without for physical problems, general health, social functioning, mental health, and the mental component summary (P < .05). WPAI:SHP scores for activity impairment, presenteeism, and overall work impairment were higher in PLwO with CVM comorbidities than in those without (P < .05), indicating lower productivity. Discussion: Increasing BMI may be linked to lower physical functioning in PLwO. Comorbidities were associated with reductions in HRQoL, with different domains affected depending on the type of comorbidity. These comorbidities were also associated with impaired work productivity. Conclusion: The presence of comorbidities, along with BMI, are important considerations for managing obesity. Reducing the prevalence of overweight or obesity is likely to benefit both individuals and wider society.

1 October 2024 in Pragmatic and Observational Research
Verified
Journal Article
Open access
PDF file
EBElisabetta Bugianesi
Elisabetta Bugianesi
LMLuca Miele
Luca Miele
GDGiovanna Donnarumma
Giovanna Donnarumma
KGKatrine Grau
Katrine Grau
MMMariarosaria Mancuso
Mariarosaria Mancuso
VHVictoria Higgins
Victoria Higgins
Background: Although the estimated prevalence of non-alcoholic steatohepatitis (NASH) in Italy is 4– 6%, little is known about patient characteristics and care pathways. Aim: To describe patient characteristics and management approaches for patients with NASH or suspected NASH in Italy. Methods: Data were drawn from the Adelphi Real World NASH Disease Specific Programme™, a cross-sectional survey of endocrinologists and gastroenterologists in Italy from January to March 2018. Physicians completed questionnaires for their next five consecutively consulting patients with NASH or suspected NASH. Analyses were descriptive. Results: Seventy-six physicians provided data on 380 patients. The mean age was 58.5 ± 11.1 years and the mean body mass index was 31.8 ± 5.5 kg/m2. A total of 231 patients (61%) had no/non-advanced fibrosis as evaluated by liver biopsy or non-invasive tests. Common diagnostic assessments were cholesterol, hemoglobin A1c, absence of viral hepatitis, and alcohol assessment. At diagnosis, 87% (n=322/372) and 45% (n=169/372) of patients received an ultrasound and liver biopsy, respectively. Overall, 88% of patients were referred from primary to secondary care. Obesity (81%) and type 2 diabetes (62%) were the most commonly recorded comorbidities, with 70% of patients having ≥ 3 comorbidities. Vitamin E (13%) and GLP-1 receptor agonists (13%) were the most prescribed guideline-recommended treatments for all patients. Conclusion: Patients with NASH in Italy had high levels of obesity and comorbidities, while diagnosis and treatment frequently were not according to guidelines. Our data show an unmet need for more targeted diagnosis and treatment in Italian patients with NASH, in order to optimize outcomes. Plain Language Summary: Fat buildup in the liver, known as fatty liver disease, affects around 4-6% of people in Italy, and can lead to complications if left untreated. However, little is known about how doctors manage people with this disease. Fatty liver disease can only be diagnosed by a liver biopsy, but we found this is only performed in 45% of people, making accurate diagnosis difficult. We also found that 28% of people receive a recommended medication. Overall, increasing doctor awareness of fatty liver medical guidelines may help improve the diagnosis and treatment for people living with fatty liver disease in Italy.